Literature DB >> 9341892

New p57KIP2 mutations in Beckwith-Wiedemann syndrome.

I Hatada1, A Nabetani, H Morisaki, Z Xin, S Ohishi, H Tonoki, N Niikawa, M Inoue, Y Komoto, A Okada, E Steichen, H Ohashi, Y Fukushima, M Nakayama, T Mukai.   

Abstract

Beckwith-Wiedemann syndrome (BWS) is characterized by numerous growth abnormalities and an increased risk of childhood tumors. The gene for BWS is localized in the 11p15.5 region, as determined by linkage analysis of autosomal dominant pedigrees. The increased maternal transmission pattern seen in the autosomal dominant-type pedigrees and the findings of paternal uniparental disomy reported for a subgroup of patients indicate that the gene for BWS is imprinted. Previously, we found p57KIP2, which is a Cdk-kinase inhibitor located at 11p15, is mutated in two BWS patients. Here, we screened for the mutation of the gene in 15 BWS patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341892     DOI: 10.1007/s004390050573

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  16 in total

1.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.

Authors:  H Watanabe; Z Q Pan; N Schreiber-Agus; R A DePinho; J Hurwitz; Y Xiong
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.

Authors:  J R Engel; A Smallwood; A Harper; M J Higgins; M Oshimura; W Reik; P N Schofield; E R Maher
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

4.  Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation.

Authors:  W W Lam; I Hatada; S Ohishi; T Mukai; J A Joyce; T R Cole; D Donnai; W Reik; P N Schofield; E R Maher
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

5.  CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.

Authors:  E M Algar; G J Deeble; P J Smith
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

Review 6.  Genetic background of adrenocortical tumor development.

Authors:  M Kjellman; C Larsson; M Bäckdahl
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

7.  Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.

Authors:  Eva-Maria D Nielsen; Lars Hansen; Trine Stissing; Keiko Yanagisawa; Knut Borch-Johnsen; Pernille Poulsen; Allan Vaag; Torben Hansen; Oluf Pedersen
Journal:  J Mol Med (Berl)       Date:  2005-04-09       Impact factor: 4.599

8.  DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain.

Authors:  Weizhen Ye; Georges Mairet-Coello; Emanuel DiCicco-Bloom
Journal:  Histochem Cell Biol       Date:  2006-10-06       Impact factor: 4.304

9.  CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.

Authors:  Ruiying Zhao; Heng-Yin Yang; Jihyun Shin; Liem Phan; Lekun Fang; Ting-Fang Che; Chun-Hui Su; Sai-Ching J Yeung; Mong-Hong Lee
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

Review 10.  Beckwith-Wiedemann syndrome.

Authors:  Rosanna Weksberg; Cheryl Shuman; J Bruce Beckwith
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.